Waterdrop Inc. Appoints Qianfei Chang as Independent Director
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2026
0mins
Source: Newsfilter
- New Board Member: Waterdrop Inc. announced the appointment of Ms. Qianfei Chang as an independent director and chair of the audit committee effective July 1, 2026, enhancing the board's expertise and governance capabilities.
- Rich Financial Background: Ms. Chang brings over 15 years of experience in financial management, equity investment, and audit oversight from prestigious institutions like China Development Bank Capital and PwC, which is expected to provide the company with deep financial expertise.
- Strategic Implications: Her appointment aims to strengthen Waterdrop's corporate governance and drive long-term growth, aligning with the company's mission to leverage technology for improving people's lives.
- Acknowledgment of Heping Feng: Waterdrop expressed gratitude for Mr. Feng's contributions, clarifying that his resignation was not due to any disputes with the company, reflecting transparency and stability in executive transitions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WDH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WDH
About WDH
Waterdrop Inc is a holding company principally engaged in the provision of insurance and healthcare service. The Company mainly operates through three segments. The Insurance segment is primarily engaged in the provision of insurance brokerage service, such as health and life insurance products, as well as technical service. The Crowdfunding segment is primarily engaged in the provision of crowdfunding service. The Others segment include online sale of health products, and the provision of digital multichannel marketing solution and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Waterdrop Inc. Appoints Qianfei Chang as Independent Director
- New Board Member: Waterdrop Inc. announced the appointment of Ms. Qianfei Chang as an independent director and chair of the audit committee effective July 1, 2026, enhancing the board's expertise and governance capabilities.
- Rich Financial Background: Ms. Chang brings over 15 years of experience in financial management, equity investment, and audit oversight from prestigious institutions like China Development Bank Capital and PwC, which is expected to provide the company with deep financial expertise.
- Strategic Implications: Her appointment aims to strengthen Waterdrop's corporate governance and drive long-term growth, aligning with the company's mission to leverage technology for improving people's lives.
- Acknowledgment of Heping Feng: Waterdrop expressed gratitude for Mr. Feng's contributions, clarifying that his resignation was not due to any disputes with the company, reflecting transparency and stability in executive transitions.
See More
Waterdrop Inc Reports 64.8% Revenue Growth in Q1 2026
- Significant Revenue Growth: Waterdrop Inc reported Q1 2026 revenue of RMB 1.24 billion, reflecting a 64.8% year-over-year increase, indicating strong market performance, particularly driven by its insurance segment, which enhances its competitive position.
- Robust Insurance Segment: The insurance business generated RMB 1.15 billion in income, up 74.1% year-over-year, driven by effective user acquisition strategies and traffic investments, showcasing the company's ongoing growth potential in the insurance sector.
- AI Technology Adoption: The company has filed 75 patent applications related to large language models, indicating its accelerated shift towards becoming an AI-native company, which is expected to enhance operational efficiency and drive future revenue growth.
- Continued Shareholder Returns: Waterdrop completed its fifth cash dividend since its IPO, distributing approximately $10.8 million to shareholders, demonstrating its commitment to returning value to investors while maintaining a strong cash reserve.
See More
Waterdrop Inc. Reports Strong Q1 2026 Financial Results
- Significant Revenue Growth: In Q1 2026, Waterdrop Inc. achieved net operating revenue of RMB 1.242 billion, representing a 64.8% year-over-year increase, indicating sustained market demand in the insurance and healthcare sectors and laying a solid foundation for the next decade.
- Consistent Profitability: The company reported a net profit of RMB 98.4 million, marking its 17th consecutive quarter of profitability, which demonstrates the stability and sustainability of its business model, thereby enhancing investor confidence.
- Strong Insurance Business: Insurance-related income grew 74.1% year-over-year, with first-year premiums facilitated by the
See More
Waterdrop Inc. Reports Strong Q1 2026 Financial Results
- Insurance Business Growth: Waterdrop's insurance-related income surged 74.1% year-over-year in Q1 2026, reflecting the company's ongoing investments in user acquisition and traffic infrastructure, which are expected to enhance its competitive position in the market.
- New Product Launch: The company introduced the 'Shouhu Ruchu' cancer insurance plan with metastasis coverage and optional recurrence benefits, achieving a 24.3% year-over-year increase in premiums for pre-existing condition insurance, aiming to broaden accessibility to insurance.
- Digital Clinical Trial Progress: The E-Find platform partnered with 243 pharmaceutical companies in Q1, enrolling 957 patients, with revenue from digital clinical trial solutions reaching approximately RMB 24.2 million, up 5.4% year-over-year, indicating strong growth potential in innovative drug trials.
- Share Repurchase Program: As of May 31, 2026, the company repurchased approximately 61.8 million ADSs for about $120.1 million and paid a cash dividend of approximately $10.8 million, demonstrating its commitment to delivering long-term value to shareholders.
See More
Waterdrop Inc. Reports Strong Q1 2026 Financial Results
- Core Business Growth: In Q1 2026, Waterdrop Inc. reported net operating revenue of RMB 1,242.2 million (approximately USD 180.1 million), reflecting a robust year-over-year increase of 64.8%, indicating strong market demand and business expansion capabilities.
- Insurance Revenue Surge: Insurance-related income reached RMB 1,145.8 million (approximately USD 166.1 million), marking a 74.1% year-over-year growth, showcasing the company's competitive edge in the insurance market and the effectiveness of its technical services.
- Crowdfunding Platform Expansion: As of March 31, 2026, the Waterdrop Medical Crowdfunding platform has attracted approximately 494 million donors, raising a total of RMB 73.5 billion to support 3.75 million patients, further solidifying its leadership position in the medical crowdfunding sector.
- Shareholder Return Program: As of May 31, 2026, the company repurchased approximately 61.8 million ADSs for about USD 120.1 million and paid a cash dividend of approximately USD 10.8 million, demonstrating a strong commitment to shareholder returns.
See More
Waterdrop Q1 Earnings: Revenue Up 64.8% Year-over-Year
- Significant Revenue Growth: Waterdrop reported Q1 revenue of RMB 180.09 million, reflecting a robust year-over-year increase of 64.8%, which underscores the company's strong growth potential in the medical crowdfunding sector and solidifies its market position.
- Insurance-Related Income Surge: The quarter saw insurance-related income reach RMB 1,145.8 million (approximately $166.1 million), marking a 74.1% increase from the same period in 2025, indicating successful promotion of insurance products and enhancing financial stability.
- Patient Donation Impact: As of March 31, 2026, approximately 494 million individuals have cumulatively donated RMB 73.5 billion to 3.75 million patients, highlighting the company's positive social impact and user engagement, which enhances its brand image.
- Clinical Trial Participation: By March 31, 2026, the company had enrolled 15,512 patients in 1,718 clinical trial programs through the E-Find platform, demonstrating its commitment to innovation and contribution to medical research.
See More
Waterdrop Inc. Appoints Qianfei Chang as Independent Director
- New Board Member: Waterdrop Inc. announced the appointment of Ms. Qianfei Chang as an independent director and chair of the audit committee effective July 1, 2026, enhancing the board's expertise and governance capabilities.
- Rich Financial Background: Ms. Chang brings over 15 years of experience in financial management, equity investment, and audit oversight from prestigious institutions like China Development Bank Capital and PwC, which is expected to provide the company with deep financial expertise.
- Strategic Implications: Her appointment aims to strengthen Waterdrop's corporate governance and drive long-term growth, aligning with the company's mission to leverage technology for improving people's lives.
- Acknowledgment of Heping Feng: Waterdrop expressed gratitude for Mr. Feng's contributions, clarifying that his resignation was not due to any disputes with the company, reflecting transparency and stability in executive transitions.
See More
Waterdrop Inc Reports 64.8% Revenue Growth in Q1 2026
- Significant Revenue Growth: Waterdrop Inc reported Q1 2026 revenue of RMB 1.24 billion, reflecting a 64.8% year-over-year increase, indicating strong market performance, particularly driven by its insurance segment, which enhances its competitive position.
- Robust Insurance Segment: The insurance business generated RMB 1.15 billion in income, up 74.1% year-over-year, driven by effective user acquisition strategies and traffic investments, showcasing the company's ongoing growth potential in the insurance sector.
- AI Technology Adoption: The company has filed 75 patent applications related to large language models, indicating its accelerated shift towards becoming an AI-native company, which is expected to enhance operational efficiency and drive future revenue growth.
- Continued Shareholder Returns: Waterdrop completed its fifth cash dividend since its IPO, distributing approximately $10.8 million to shareholders, demonstrating its commitment to returning value to investors while maintaining a strong cash reserve.
See More
Waterdrop Inc. Reports Strong Q1 2026 Financial Results
- Significant Revenue Growth: In Q1 2026, Waterdrop Inc. achieved net operating revenue of RMB 1.242 billion, representing a 64.8% year-over-year increase, indicating sustained market demand in the insurance and healthcare sectors and laying a solid foundation for the next decade.
- Consistent Profitability: The company reported a net profit of RMB 98.4 million, marking its 17th consecutive quarter of profitability, which demonstrates the stability and sustainability of its business model, thereby enhancing investor confidence.
- Strong Insurance Business: Insurance-related income grew 74.1% year-over-year, with first-year premiums facilitated by the
See More
Waterdrop Inc. Reports Strong Q1 2026 Financial Results
- Insurance Business Growth: Waterdrop's insurance-related income surged 74.1% year-over-year in Q1 2026, reflecting the company's ongoing investments in user acquisition and traffic infrastructure, which are expected to enhance its competitive position in the market.
- New Product Launch: The company introduced the 'Shouhu Ruchu' cancer insurance plan with metastasis coverage and optional recurrence benefits, achieving a 24.3% year-over-year increase in premiums for pre-existing condition insurance, aiming to broaden accessibility to insurance.
- Digital Clinical Trial Progress: The E-Find platform partnered with 243 pharmaceutical companies in Q1, enrolling 957 patients, with revenue from digital clinical trial solutions reaching approximately RMB 24.2 million, up 5.4% year-over-year, indicating strong growth potential in innovative drug trials.
- Share Repurchase Program: As of May 31, 2026, the company repurchased approximately 61.8 million ADSs for about $120.1 million and paid a cash dividend of approximately $10.8 million, demonstrating its commitment to delivering long-term value to shareholders.
See More
Waterdrop Inc. Reports Strong Q1 2026 Financial Results
- Core Business Growth: In Q1 2026, Waterdrop Inc. reported net operating revenue of RMB 1,242.2 million (approximately USD 180.1 million), reflecting a robust year-over-year increase of 64.8%, indicating strong market demand and business expansion capabilities.
- Insurance Revenue Surge: Insurance-related income reached RMB 1,145.8 million (approximately USD 166.1 million), marking a 74.1% year-over-year growth, showcasing the company's competitive edge in the insurance market and the effectiveness of its technical services.
- Crowdfunding Platform Expansion: As of March 31, 2026, the Waterdrop Medical Crowdfunding platform has attracted approximately 494 million donors, raising a total of RMB 73.5 billion to support 3.75 million patients, further solidifying its leadership position in the medical crowdfunding sector.
- Shareholder Return Program: As of May 31, 2026, the company repurchased approximately 61.8 million ADSs for about USD 120.1 million and paid a cash dividend of approximately USD 10.8 million, demonstrating a strong commitment to shareholder returns.
See More
Waterdrop Q1 Earnings: Revenue Up 64.8% Year-over-Year
- Significant Revenue Growth: Waterdrop reported Q1 revenue of RMB 180.09 million, reflecting a robust year-over-year increase of 64.8%, which underscores the company's strong growth potential in the medical crowdfunding sector and solidifies its market position.
- Insurance-Related Income Surge: The quarter saw insurance-related income reach RMB 1,145.8 million (approximately $166.1 million), marking a 74.1% increase from the same period in 2025, indicating successful promotion of insurance products and enhancing financial stability.
- Patient Donation Impact: As of March 31, 2026, approximately 494 million individuals have cumulatively donated RMB 73.5 billion to 3.75 million patients, highlighting the company's positive social impact and user engagement, which enhances its brand image.
- Clinical Trial Participation: By March 31, 2026, the company had enrolled 15,512 patients in 1,718 clinical trial programs through the E-Find platform, demonstrating its commitment to innovation and contribution to medical research.
See More
